315 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
2 May 24
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
8:11am
, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
15 Feb 24
Results of Operations and Financial Condition
8:10am
, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well
8-K
EX-99.1
rbegdulbrbj
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
8-K
EX-99.1
10hdc2p
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
gqnu8d pqj21mg
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
EX-99.1
o76j0epbja9if
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
wjgx vt3ovojgjnrm5u
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
x51qrr
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
EX-99.1
nea ir6f7
4 May 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
jpto2olh8rv89uhzpz5
27 Oct 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.2
0jfc 4248clhr
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm